Snore Centre opens a new clinic in Richmond, London - Sleep apnoea could be misdiagnosed as depression - Try the Snore Centre Mobile App - OSA common in Type 1 Diabetes
A new Sleeping Disorders Centre clinic opened at Hampton Hill Medical Centre (TW12 1NY) on 12th September.
Richmond Clinical Commissioning Group (CCG) has commissioned a community based OSA service, which is available to people who have been referred by their GP. It is one of the first of its kind in the country and allows patients to be assessed and monitored in the comfort of their own home.
The service has been developed in partnership with consultant ear, nose and throat surgeons and Department of Health OSA advisors, Professor Ram Dhillon and Mr Michael Oko.
Dr Graham Lewis, local GP and chair of Richmond CCG, said: “For some people who snore, the cause will be OSA. It is a common, treatable condition, but many people don’t know they have it and require diagnosis. It is important to make an appointment to see your GP if you have any symptoms.â€
The service allows many of the patients with suspected OSA or those with established OSA to be diagnosed and monitored in their own bed, without having to spend a night away from home.
Dr Lewis continues: “The good news is that we can help 80% of patients manage the condition at home, without the need for surgery. This could be anything from lifestyle changes to state-of-the-art technology which enables us to track the progress of a patient at the touch of a button.
“We are very pleased to be offering this innovative service for people living in the borough of Richmond who have suspected obstructive sleep apnoea.â€
More than 70% of people with sleep apnoea experience symptoms of depression, according to a new study published in the Journal of Clinical Sleep Medicine. Researchers say their findings indicate a possibility that the sleep condition could be misdiagnosed as depression.
Researchers found CPAP was effective reducing depressive symptoms among patients with sleep apnoea. However, the study also finds depressive symptoms among sleep apnoea patients can be relieved with the use of continuous positive airway pressure (CPAP) therapy.
Previous studies have suggested sleep apnoea can raise the risk for depression if left untreated, and the condition has been linked to increased risk for high blood pressure, heart disease, stroke and type 2 diabetes.
In this latest study, Dr. David R. Hillman, clinical professor at the University of Western Australia, and colleagues set out to gain a better understanding of the prevalence of depressive symptoms among individuals with sleep apnoea, and to investigate whether CPAP may be effective for reducing these symptoms.
The team enrolled 426 individuals - 243 men and 183 women - who had been referred to a hospital sleep center with suspected sleep apnoea.Sleep apnoea was diagnosed in 293 participants, of whom 213 (73%) had symptoms of depression at study baseline. The greater the severity of sleep apnoea, the higher the likelihood of depressive symptoms, the researchers found.
Participants who were diagnosed with sleep apnoea were offered CPAP therapy 5 hours a night for 3 months. Treatment compliance was recorded, and the PHQ-9 was repeated after treatment ceased to determine participants' symptoms of depression.
The researchers found that the 228 participants with sleep apnoea who adhered to CPAP therapy experienced a significant reduction in depressive symptoms after 3 months; once treatment ceased, only 9 (4%) of these participants had clinically significant symptoms of depression. What is more, the team found that of the 41 participants with sleep apnoea who reported feelings of self-harm or suicidal thoughts at study baseline, none reported any such feelings after 3 months of CPAP.
Have You Tried Our Mobile App?
Keep up with all the latest news and research on sleep apnoea from the Sleeping Disorders Centre with this nifty free app. Here you can find all our social media channels (YouTube/Facebook/Twitter/Blog) all in one place, right on your phone.
Be sure to let us know what you think of our app by leaving a review on iTunes or the Google Play Store. All your feedback is valuable to us.
Obstructive sleep apnoea (OSA) is common in people with type 1 diabetes and is associated with abnormal glycemia and microvascular complications but not body mass index (BMI), a new study finds.
The data were presented June 7, 2015 at the American Diabetes Association (ADA) 2015 Scientific Sessions by Laurent Meyer, MD, an endocrinologist at Hopitaux Universitaires de Strasbourg, France.
The link between type 1 diabetes and OSA has been reported in three previous small trials, but this study of 90 adults with type 1 diabetes is the largest such trial to date and the first to use both continuous glucose monitoring and sleep studies to investigate the relationship between OSA and both hypo- and hyperglycemic variation, Dr Meyer explained.
In the study, OSA was particularly common among those with long disease duration and was associated with higher rates of diabetes complications, including retinopathy and peripheral neuropathy.
"The main message for clinicians is to think of OSA in type 1 patients with a long duration of diabetes. With the design of our study we can't say check at 10 or 15 years, but in my opinion if [a patient has] a duration of more than 20 years, it's important to check for OSA," Dr Meyer told Medscape Medical News in an interview.
Sleep apnoea is ordinarily associated with obesity, but the French patients in this study were not excessively overweight, with a mean BMI of 26 kg/m2, suggesting that the OSA may be due to other factors.
"In our study the BMI was near normal.…I think perhaps it's linked to cardiac autonomic neuropathy.…Like other degenerative complications, it may be linked to an infiltration of soft tissue in the upper airways by glycated products. I think OSA must be considered a degenerative complication [of diabetes], like neuropathy or retinopathy," Dr Meyer said.
